Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.
Nicholas M. Bernthal(Harvard University), Emanuela Palmerini(Istituto Ortopedico Rizzoli), John H. Healey(Memorial Sloan Kettering Cancer Center), Hans Gelderblom(Leiden University Medical Center), Michiel A. J. van de Sande(Leiden University Medical Center), Sebastian Bauer(Science for Life Laboratory), Julio López Bastida(University of Castilla-La Mancha), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Xin Ye(University of Georgia), Geert Spierenburg(Leiden University Medical Center), Petra Laeis(Daiichi Sankyo (Germany)), Eva‐Maria Fronk(Daiichi Sankyo (Germany)), Eric L. Staals(Istituto Ortopedico Rizzoli)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k